Leerink initiated coverage of Edwards Lifesciences with a Market Perform rating and $75 price target. Overall, the firm sees a balanced risk-reward setup for Edwards Lifesciences over the next 12 months, with shares likely to experience continued volatility into several key upcoming TAVRspecific catalysts starting at TCT in San Francisco next week that could have significant read-through for EW. Additionally, Leerink’s MEDACorp U.S. TAVR survey results indicate Edwards Lifesciences may see accelerated market share erosion in 2024 as emerging competition gains traction. Looking ahead, the firm sees opportunities for Edwards Lifesciences to accelerate TAVR growth by unlocking incremental commercial opportunities, with topline results from the EARLY TAVR study in asymptomatic severe AS expected in the first half of 2024. However, it remains on the sidelines for now.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target lowered to $83 from $105 at Truist
- Edwards Lifesciences put volume heavy and directionally bearish
- Citi cuts Edwards Lifesciences target, opens ‘negative catalyst watch’
- Edwards Lifesciences (EW) Under the Radar of EU Antitrust Regulators
- Edwards tells Reuters cooperating with EU antitrust regulators after raid
